tamiflop now the looser relenza the winner, page-12

Hi Miso,

I have been a follower of Biota for many years as you maybe know. And just like yourself have been very frustrated with the lack of commitment of GSK towards Relenza.

Thats all in the market and old news although still relevent to keep in the back of your head before you invest in Biota for the Relenza product.

Because as you know all the other products that are at verious stages in the pipe line are not in the hands of GSK but other Companies.

What I have been trying to say with my previous posts is that the Relenza story is now looking to change due to the now widely excepted and publisished fact that Tamiflu is now basically an antiviral of the past as it does not same to do is job any longer with most of the flue strains.

This will assure that Relenza will be on a winner streak for the coming 6 years and Biota will make some good money out of it.

The UK order is prove that perception towards Relenza has changed and I can assure you that other Countries who are in the process to re-new or adding to their antiviral stockpiles have taken note of this.

I could ofcourse be totaly wrong with this but do not believe so.

Time will tell but imho the future looks very bright for Biota.

good luck

jojo